170 related articles for article (PubMed ID: 37775744)
1. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
4. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
Xu B; Yin Y; Dong M; Song Y; Li W; Huang X; Wang T; He J; Mu X; Li L; Mu S; Zhang W; Li M
Cancer Med; 2021 Jan; 10(1):109-118. PubMed ID: 33128299
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
7. Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial.
Xu Y; Huang Z; Fang J; Liu A; Lu H; Yu X; Chen K; Xu X; Ma X; Shi W; Kim YH; Hakozaki T; Addeo A; Shen Y; Li S; Fan Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1069-1078. PubMed ID: 35832454
[TBL] [Abstract][Full Text] [Related]
8. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Malhotra MK; Pahuja S; Kiesel BF; Appleman LJ; Ding F; Lin Y; Tawbi HA; Stoller RG; Lee JJ; Belani CP; Chen AP; Giranda VL; Shepherd SP; Emens LA; Ivy SP; Chu E; Beumer JH; Puhalla S
Breast Cancer Res Treat; 2023 Apr; 198(3):487-498. PubMed ID: 36853577
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Batalini F; Xiong N; Tayob N; Polak M; Eismann J; Cantley LC; Shapiro GI; Adalsteinsson V; Winer EP; Konstantinopoulos PA; D'Andrea A; Swisher EM; Matulonis UA; Wulf GM; Mayer EL
Clin Cancer Res; 2022 Apr; 28(8):1493-1499. PubMed ID: 35149538
[TBL] [Abstract][Full Text] [Related]
12. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
13. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
14. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients].
Ou KP; Li Q; Luo Y; Lyu JJ; Zhou H; Yang Y; Cai YJ; Wang ZJ; Wang X; Qi LQ; Ma F; Xu BH
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):966-971. PubMed ID: 33256310
[No Abstract] [Full Text] [Related]
17. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
Li H; Liu R; Shao B; Ran R; Song G; Wang K; Shi Y; Liu J; Hu W; Chen F; Liu X; Zhang G; Zhao C; Jia R; Wang Q; Rugo HS; Zhang Y; Li G; Xu J
Chin J Cancer Res; 2020 Jun; 32(3):370-382. PubMed ID: 32694901
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
